RhoVac Valuation

Is RHOVAC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RHOVAC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RHOVAC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RHOVAC's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RHOVAC?

Key metric: As RHOVAC is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for RHOVAC. This is calculated by dividing RHOVAC's market cap by their current book value.
What is RHOVAC's PB Ratio?
PB Ratio	1.7x
Book	SEK 12.78m
Market Cap	SEK 22.09m

RHOVAC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does RHOVAC's PB Ratio compare to its peers?

The above table shows the PB ratio for RHOVAC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	1.2x
LPGO Lipigon Pharmaceuticals	1x	126.3%	SEK 25.1m
SCOL Scandion Oncology	0.5x	69.7%	SEK 17.5m
LIDDS LIDDS	2.4x	n/a	SEK 14.4m
GEAN Genetic Analysis	0.9x	n/a	NOK 20.2m
RHOVAC RhoVac	1.7x	n/a	SEK 22.1m

Price-To-Book vs Peers: RHOVAC is good value based on its Price-To-Book Ratio (1.7x) compared to the peer average (4.1x).

Price to Book Ratio vs Industry

How does RHOVAC's PB Ratio compare vs other companies in the SE Biotechs Industry?

8 Companies	Price / Book	Estimated Growth	Market Cap
COMBI CombiGene	0.6x	n/a	US$4.62m
SCOL Scandion Oncology	0.5x	69.7%	US$1.58m
DIABIO Diagonal Bio	0.5x	n/a	US$1.19m
CYXO Cyxone	0.4x	n/a	US$1.00m

8 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: RHOVAC is good value based on its Price-To-Book Ratio (1.7x) compared to the Swedish Biotechs industry average (2.2x).

Price to Book Ratio vs Fair Ratio

What is RHOVAC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RHOVAC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	1.7x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate RHOVAC's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

AstraZeneca

UK£156.0b

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

AZN

UK£1,413.50

-1.8%

4.5%

Swedish Orphan Biovitrum

SEK 99.8b

An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.

SOBI

SEK 290.60

-12.4%

15.7%

PMD Device Solutions

SEK 33.2m

A digital medical device company, develops and sells respiratory monitoring solutions in Ireland.

PMDS

SEK 1.28

-14.7%

n/a